Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation Study to Evaluate Safety, Tolerability Dosimetry, Pharmacokinetics and Preliminary Efficacy of 131I-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients

NCT02602067 is registered in ClinicalTrials.gov with sigma-tau i.f.r. S.p.A. as lead sponsor.

NCT NCT02602067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02602067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation Study to Evaluate Safety, Tolerability Dosimetry, Pharmacokinetics and Preliminary Efficacy of 131I-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients
Lead sponsor
sigma-tau i.f.r. S.p.A.
Phase
Phase 1
Overall status
Terminated
Start date
November 30, 2015
Completion date
April 30, 2017
Enrollment
2 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasm, connective and soft tissue neoplasm, digestive system neoplasm, head and neck neoplasm, lymphoma, non-hodgkin, pancreatic neoplasm, respiratory tract neoplasm, skin neoplasm, urogenital neoplasm